Various doses of statins and coronary angiogenesis in patients with coronary heart disease
Abstract
Aim. To investigate the effects of different doses of statins on the levels of factors stimulating and inhibiting coronary angiogenesis.
Material and methods. The study included 90 patients with coronary heart disease (CHD), Functional Class I-III stable angina, and 30 healthy volunteers. All patients underwent clinical examination, electrocardiography, veloergometry, and echocardiography. At baseline, blood lipid levels were measured. Serum levels of vascular endothelial growth factor (VEGF), transforming growth factor (TGF-pi), and endostatin were measured twice — before statin therapy and 3 months after it started. Daily rosuvastatin dose was 5, 10, or 40 mg.
Results. Statin therapy resulted in reduced levels of angiogenesis-stimulating factors, such as VEGF and TGF. The level of endostatin, which inhibits angiogenesis, did not change substantially. Similar effects were observed for doses of 5, 10, and 40 mg/d.
Conclusion. The results obtained disagree with the hypothesis of dose-dependent effects of statins on angiogenesis. Both low doses of statins and aggressive statin therapy affect angiogenesis factors similarly.
About the Authors
I. V. Sergienko
Russian Cardiology Scientific and Research Complex
Russian Federation
Russian Federation
Moscow
A. E. Semenova
Russian Cardiology Scientific and Research Complex
Russian Federation
Russian Federation
Moscow
V. V. Masenko
Russian Cardiology Scientific and Research Complex
Russian Federation
Russian Federation
Moscow
S. A. Gabrusenko
Russian Cardiology Scientific and Research Complex
Russian Federation
Russian Federation
Moscow
V. V. Kukharchuk
Russian Cardiology Scientific and Research Complex
Russian Federation
Russian Federation
Moscow
Yu. N. Belenkov
Russian Cardiology Scientific and Research Complex
Russian Federation
Russian Federation
Moscow
References
1. Сергиенко И.В., Габрусенко С.А., Малахов В.В. и др. Влияние наружной контрпульсации на перфузию миокарда левого желудочка у больных ИБС. Кардиоваск тер профил 2008; 7: 85-90.
2. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. JACC 2007; 49: 2102-4.
3. Jain RK, Finn AV, Kolodgie FD, et al. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007; 4: 491-502.
4. Miura S, Saku K. Regulation of angiogenesis and angiogenic factors by cardiovascular medications. Curr Pharm Des 2007; 13(20): 2113-7.
5. Trape J, Morales C, Molina R, et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand J Clin Lab Invest 2006; 66(3): 261-7.
6. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003; 170(2): 229-36.
7. Li TS, Takahashi M, Suzuki R, et al. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann Thorac Surg 2006; 81: 2217-25.
8. Boodhwani M, Nakai Y, Voisine P, et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006; 114: I402-8.
9. Yamada K, Sakurai E, Itaya M, et al. Invest. Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. Ophthalmol Vis Sci 2007; 48(4): 1839-43.
10. Sagara N, Kawaji T, Takano A, et al. Effect of pitavastatin on experimental choroidal neovascularization in rats. Exp Eye Res 2007; 84(6): 1074-80.
11. Boodhwani M, Mieno S, Voisine P, et al. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. J Thorac Cardiovasc Surg 2006; 132(6): 1299-306.
12. Boodhwani M, Mieno S, Feng J, et al. Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. J Thorac Cardiovasc Surg 2008; 135(1): 117-22.
13. Giurgea AG, Margeta C, Maca T, et al. Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol. 2006; 47(1): 30-6.
14. Alber HF, Dulak J, Frick M, et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. JACC 2002; 39(12): 1951-5.
15. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 1998; 129: 1050-60.
16. Руда М.Я., Зыско А.П. Инфаркт миокарда. Москва 1977.
Review
For citations:
Sergienko I.V., Semenova A.E., Masenko V.V., Gabrusenko S.A., Kukharchuk V.V., Belenkov Yu.N. Various doses of statins and coronary angiogenesis in patients with coronary heart disease. Cardiovascular Therapy and Prevention. 2009;8(5):22-27. (In Russ.)
Views:
447
Email this article 
